Tarsus Pharmaceuticals TARS
$73.01 −$4.66 (-6.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $71.00 -2.75%
Open$77.09
Prev close$77.67
Day range$72.57 – $78.11
Volume706.8K
Market cap$3.60B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$194.57M+63.9% YoY
Operating profit-$663.71M-4,468.2% YoY
Net profit-$668.33M-5,210.6% YoY
Diluted EPS-$14.40-4,700.0% YoY
Free cash flow-$44.51M-372.3% YoY
Operating cash flow-$6.00M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin93.2%
Operating margin-102.3%
Net margin-102.9%
Return on equity-319.8%
Return on assets-135.0%
Return on invested capital-241.8%
Current ratio1.96
Liabilities / assets79.4%
Cash & investments$309.61M
Total debt$72.94M
Net cash (debt)$236.68M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $194.57M | $173.91M | $162.05M | $451.36M | $151.67M |
| Total Operating Revenue | $194.57M | $173.91M | $162.05M | $451.36M | $151.67M |
| Cost of Revenue | $13.89M | $12.11M | $9.40M | $30.68M | $10.93M |
| Gross Profit | $180.68M | $161.80M | $152.66M | $420.68M | $140.74M |
| Operating Expense | $844.39M | $181.71M | $158.78M | $491.65M | $148.72M |
| Selling and Admin Expenses | $168.02M | $150.70M | $136.43M | $427.32M | $130.68M |
| Research & Development | $676.37M | $31.01M | $22.35M | $64.32M | $18.04M |
| Operating Profit | -$663.71M | -$19.91M | -$6.12M | -$70.97M | -$7.98M |
| Net Non-Operating Interest Income (Expense) | $1.59M | $1.54M | $1.59M | $6.81M | $1.74M |
| Non-Operating Interest Income | $3.78M | $3.70M | $3.72M | $15.75M | $3.95M |
| Non-Operating Interest Expense | $2.01M | $1.99M | $1.97M | $8.34M | $2.06M |
| Total Other Finance Costs | $172,000.00 | $165,000.00 | $159,000.00 | $593,000.00 | $156,000.00 |
| Other Income (Expense) | -$1.57M | $2.53M | -$87,000.00 | -$202,000.00 | -$74,000.00 |
| Special Income (Charges) | -$1.66M | – | – | $0.00 | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | $1.66M | – | – | – | – |
| Other Non-Operating Income (Expenses) | $91,000.00 | -$281,000.00 | -$87,000.00 | -$202,000.00 | -$74,000.00 |
| Pretax Profit | -$663.69M | -$15.84M | -$4.62M | -$64.36M | -$6.31M |
| Tax | $4.64M | $2.72M | $2.35M | $2.06M | $2.06M |
| Net Profit | -$668.33M | -$18.55M | -$6.97M | -$66.42M | -$8.37M |
| Profit from Continuing Operations | -$668.33M | -$18.55M | -$6.97M | -$66.42M | -$8.37M |
| Net Income to Parent Company | -$668.33M | -$18.55M | -$6.97M | -$66.42M | -$8.37M |
| Net Income to Common Stockholders | -$668.33M | -$18.55M | -$6.97M | -$66.42M | -$8.37M |
| Basic EPS | -$14.40 | -$0.43 | -$0.16 | -$1.59 | -$0.20 |
| Diluted EPS | -$14.40 | -$0.43 | -$0.16 | -$1.59 | -$0.20 |
| Gain on Sale of Security | – | $2.81M | – | – | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $505.50M | $611.14M | $581.14M | $562.16M | $562.16M |
| Total Current Assets | $445.42M | $561.99M | $537.23M | $522.78M | $522.78M |
| Cash and Cash Equivalents & Short-Term Investments | $309.61M | $449.69M | $388.73M | $417.27M | $417.27M |
| -Cash and Cash Equivalents | $136.53M | $204.60M | $102.19M | $183.64M | $183.64M |
| -Short Term Investments | $173.08M | $245.10M | $286.54M | $233.63M | $233.63M |
| Receivables | $102.11M | $98.31M | $117.21M | $87.11M | $87.11M |
| -Accounts Receivable | $100.44M | $96.03M | $100.34M | $85.06M | $85.06M |
| -Other Receivables | $1.67M | $2.28M | $16.86M | $2.05M | $2.05M |
| Prepaid Assets | $28.54M | $9.61M | $26.72M | $13.47M | $13.47M |
| Inventory | $5.16M | $4.38M | $4.57M | $4.37M | $4.37M |
| Restricted Cash | $0.00 | $0.00 | $0.00 | $560,000.00 | $560,000.00 |
| Total Non-Current Assets | $60.08M | $49.15M | $43.91M | $39.38M | $39.38M |
| Net PPE | $31.11M | $30.40M | $27.67M | $21.75M | $21.75M |
| -Gross PPE | $33.84M | $32.25M | $29.96M | $23.84M | $23.84M |
| -Accumulated Depreciation | -$2.73M | -$1.85M | -$2.30M | -$2.10M | -$2.10M |
| Investments and Advances | $6.68M | $6.68M | $3.87M | $3.87M | $3.87M |
| Goodwill and Other Intangible Assets | $16.65M | $6.89M | $7.13M | $7.37M | $7.37M |
| Other Non-Current Assets | $5.64M | $5.19M | $5.24M | $6.40M | $6.40M |
| Total Liabilities | $401.47M | $264.41M | $232.18M | $218.73M | $218.73M |
| Total Current Liabilities | $227.11M | $175.75M | $143.51M | $135.70M | $135.70M |
| Payables | $52.16M | $51.64M | $31.96M | $27.30M | $27.30M |
| -Accounts Payable | $34.69M | $40.14M | $24.13M | $16.39M | $16.39M |
| -Total Tax Payable | $5.67M | $2.11M | $563,000.00 | $1.81M | $1.81M |
| -Other Payable | $11.80M | $9.39M | $7.27M | $9.10M | $9.10M |
| Current Accrued Expenses | $122.01M | $98.69M | $79.05M | $86.22M | $86.22M |
| Other Current Liabilities | $52.94M | $25.43M | $32.50M | $22.18M | $22.18M |
| Total Non-Current Liabilities | $174.36M | $88.66M | $88.68M | $83.04M | $83.04M |
| Long Term Debt and Capital Lease Obligation | $72.94M | $72.76M | $72.60M | $72.44M | $72.44M |
| -Long Term Debt | $72.94M | $72.76M | $72.60M | $72.44M | $72.44M |
| Other Non-Current Liabilities | $101.42M | $15.90M | $16.08M | $10.60M | $10.60M |
| Total Equity | $104.03M | $346.73M | $348.95M | $343.43M | $343.43M |
| Stockholders' Equity | $104.03M | $346.73M | $348.95M | $343.43M | $343.43M |
| Capital Stock | $7,000.00 | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 |
| -Common Stock | $7,000.00 | $6,000.00 | $6,000.00 | $6,000.00 | $6,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.23B | $799.43M | $782.84M | $769.67M | $769.67M |
| Retained Earnings | -$1.12B | -$452.15M | -$433.60M | -$426.63M | -$426.63M |
| Gains/Losses Not Affecting Retained Earnings | -$914,000.00 | -$557,000.00 | -$298,000.00 | $381,000.00 | $381,000.00 |
| -Current Capital Lease Obligation | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$6.00M | $61.22M | -$24.65M | -$12.45M | $19.33M |
| Net cash flow from continuing operations | -$6.00M | $61.22M | -$24.65M | -$12.45M | $19.33M |
| Net Income from Continuing Operations | -$668.33M | -$18.55M | -$6.97M | -$66.42M | -$8.37M |
| Gain/Loss from Continuing Operations | $1.67M | – | – | – | – |
| Depreciation & Depletion & Amortization | $1.03M | $1.00M | $437,000.00 | $1.82M | $443,000.00 |
| Other Non-Cash Items | $632.48M | $258,000.00 | $236,000.00 | $1.28M | $310,000.00 |
| Change in Working Capital | -$2.66M | $68.63M | -$29.48M | $14.64M | $13.58M |
| -Change in Receivables | -$3.80M | $18.92M | -$30.10M | -$39.05M | -$12.77M |
| -Change in Inventory | -$781,000.00 | $198,000.00 | -$196,000.00 | -$1.75M | -$536,000.00 |
| -Change in Prepaid Assets | -$16.70M | $17.11M | -$13.24M | $1.72M | $8.19M |
| -Change in Payables and Accrued Expense | $2.38M | $19.05M | -$1.54M | $8.86M | $19.20M |
| -Change in Other Current Assets | -$77,000.00 | $55,000.00 | $141,000.00 | -$527,000.00 | -$381,000.00 |
| -Change in Other Current Liabilities | $16.32M | $13.30M | $15.46M | $45.39M | -$119,000.00 |
| Net cash flow from investing | -$189.49M | $37.88M | -$58.56M | -$42.12M | $49.27M |
| Net Cash Flow from Continuing Investing Activities | -$189.49M | $37.88M | -$58.56M | -$42.12M | $49.27M |
| Net PPE Purchase and Sale | -$1.21M | -$4.07M | -$5.82M | -$9.86M | -$6.36M |
| Net Investment Purchase and Sale | -$150.99M | $41.95M | -$52.74M | -$32.26M | $55.63M |
| Financing Cash Flow | $127.81M | $3.30M | $1.20M | $143.39M | $2.31M |
| Net Cash Flow from Continuing Financing Activities | $127.81M | $3.30M | $1.20M | $143.39M | $2.31M |
| Net Common Stock Issuance | $113.14M | $0.00 | $0.00 | $134.77M | $0.00 |
| Proceeds from Stock Option Exercised | $7.48M | $3.30M | $1.20M | $8.62M | $2.31M |
| Ending Cash Balance | $138.91M | $206.60M | $104.19M | $186.20M | $186.20M |
| Net Change in Cash | -$67.68M | $102.40M | -$82.01M | $88.82M | $70.92M |
| Beginning Cash Balance | $206.60M | $104.19M | $186.20M | $97.38M | $115.29M |
| Free Cash Flow | -$44.51M | $57.15M | -$30.47M | -$22.31M | $12.97M |
| Net Intangibles Purchase and Sale | – | – | – | $0.00 | $0.00 |
| Net Issuance Payments Of Debt | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on TARS.
Sign in to join the discussion.